Business
Sareum notes Sierra Oncology Q1 2019 Results
Sareum notes Sierra Oncology Q1 2019 Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3945Y Sareum Holdings PLC 08 May 2019 \n\n(AIM: SAR) 8 May 2019\n \nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nLicence holder for SRA737, Sierra Oncology, has reported its Q1 2019 Results\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (\"Sierra\"), the licence holder advancing clinical cancer candidate SRA737, has announced its results for the first quarter 2019. In the statement, Sierra provides a summary of the status and recent progress made on the development of SRA737, a novel Chk1 inhibitor, in clinical and preclinical studies.\n \nCommenting on the SRA737 programme, Dr Nick Glover, Sierra's CEO said: \"Subsequent to the end of the quarter, we reported compelling preclinical data for SRA737+LDG, our oral Chk1 inhibitor (SRA737) plus non-cytotoxic low dose gemcitabine (LDG), in combination with immunotherapy, in a late-breaking oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019. These data highlight the ability for this unique combination to function synergistically and demonstrate significant efficacy in an immunotherapy resistant small cell lung cancer (SCLC) model. We are also currently in the process of analysing preliminary data from our two ongoing Phase 1/2 clinical trials evaluating SRA737 monotherapy and SRA737+LDG combination therapy, and expect to report on these studies and potential next steps in the development path for SRA...